Literature DB >> 12534577

Central 5-HT receptor hypersensitivity in migraine without aura.

E M Cassidy1, E Tomkins, T Dinan, O Hardiman, V O'Keane.   

Abstract

Serotonin has long been implicated as a key neurotransmitter in migraine. There is a dearth of research specifically examining 5-HT1A receptor sensitivity in migraine despite the importance of this receptor in regulating central serotonergic tone. In this study we examined the hypothesis that migraine without aura is associated with hypersensitivity of central 5-HT1A receptors, using a 5-HT1A neuroendocrine challenge drug and comparing serum prolactin responses between a test group with migraine and a matched group of healthy controls. Twelve female subjects fulfilling International Headache Society (IHS) criteria for migraine without aura were evaluated. Following an overnight fast, subjects presented for testing at 9am. An intravenous canula was inserted and serum prolactin was assessed at baseline and every 30 min for 3 h following a single dose of 30 mg oral buspirone, a 5-HT1A-receptor agonist. Subjects were assessed during the first 5 days of the menstrual cycle. No subjects were taking psychotropic medication or migraine prophylactic treatment. Patients with current or previous psychiatric disorder, daily headache or analgesic overuse were excluded. 16 healthy female volunteers matched for age and menstrual status were also evaluated and served as controls. There was no difference in baseline prolactin between groups. There was a significant rise in prolactin following buspirone in both groups. Subjects with migraine had a significantly increased prolactin response to buspirone (delta max) compared to controls (P < 0.001). This study supports the hypothesis that migraine without aura is associated with a relative hypersensitivity of central 5-HT1A receptors. This is of relevance given the role of the 5-HT1A receptor in controlling raphe 5-HT tone and in the possible association between migraine and anxiety and depression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12534577     DOI: 10.1046/j.1468-2982.2003.00441.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  7 in total

1.  Evidence for hyperprolactinemia in migraineurs: a systematic review and meta-analysis.

Authors:  Ali Noori-Zadeh; Morvarid Karamkhani; Ali Seidkhani-Nahal; Afra Khosravi; Shahram Darabi
Journal:  Neurol Sci       Date:  2019-08-23       Impact factor: 3.307

Review 2.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

3.  Paroxetine engenders analgesic effects through inhibition of p38 phosphorylation in a rat migraine model.

Authors:  Chuanming Wang; Wei Bi; Yanran Liang; Xiuna Jing; Songhua Xiao; Yannan Fang; Qiaoyun Shi; Enxiang Tao
Journal:  Neural Regen Res       Date:  2012-05-05       Impact factor: 5.135

4.  Serum prolactin and migraine.

Authors:  S Ali Masoud; E Fakharian
Journal:  Ann Saudi Med       Date:  2005 Nov-Dec       Impact factor: 1.526

Review 5.  An Association of Serotonin with Pain Disorders and Its Modulation by Estrogens.

Authors:  Stephania Paredes; Santiago Cantillo; Kenneth D Candido; Nebojsa Nick Knezevic
Journal:  Int J Mol Sci       Date:  2019-11-15       Impact factor: 5.923

Review 6.  Headache in essential thrombocythaemia.

Authors:  R Frewin; A Dowson
Journal:  Int J Clin Pract       Date:  2012-08-14       Impact factor: 2.503

Review 7.  A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection.

Authors:  Sheena K Aurora; Stephen B Shrewsbury; Sutapa Ray; Nada Hindiyeh; Linda Nguyen
Journal:  Headache       Date:  2021-04-01       Impact factor: 5.887

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.